Jenny Herman sold $21k of SDGR
SVP & Controller at Schrodinger, Inc.. 859 shares at an average of $24.43, traded Feb 11, 2025, filed Feb 12, 2025.
Score components
- +15RoleOfficer
- 0Trade size$21k at market
- 0Share of holdings soldSold 4.5% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001490978-25-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 11, 2025 | SOpen-market sale Common Stock10b5-1 | -859 | $24.43 | $21k | 18,215 | Feb 12, 2025 |
Related signals
Other insiders at Schrodinger, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Schrodinger, Inc. | Karen Akinsanya See Remarks | $928k 31,599 shares | -31% | |
| 0Weak | Schrodinger, Inc. | Margaret Dugan Chief Medical Officer | $29k 1,395 shares | -5% | |
| 21Weak | Schrodinger, Inc. | Karen Akinsanya President of R&D, Therapeutics | $420k 16,723 shares | -52% | |
| 0Weak | Schrodinger, Inc. | Jenny Herman SVP & Controller | $14k 666 shares | -2% | |
| 13Weak | Schrodinger, Inc. | Robert Lorne Abel See Remarks | $32k 1,225 shares | -13% | |
| 5Weak | Schrodinger, Inc. | Margaret Dugan Chief Medical Officer | $27k 1,531 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.